A
Andrew Farb
Researcher at Food and Drug Administration
Publications - 192
Citations - 36289
Andrew Farb is an academic researcher from Food and Drug Administration. The author has contributed to research in topics: Restenosis & Stent. The author has an hindex of 68, co-authored 183 publications receiving 33647 citations. Previous affiliations of Andrew Farb include Center for Drug Evaluation and Research & Northwestern University.
Papers
More filters
Journal ArticleDOI
Lessons From Sudden Coronary Death A Comprehensive Morphological Classification Scheme for Atherosclerotic Lesions
TL;DR: This review will reconsider the current paradigm for understanding the critical, final steps in the progression of atherosclerotic lesions, and devise a simpler classification scheme that is consistent with the AHA categories but is easier to use, able to deal with a wide array of morphological variations, and not overly burdened by mechanistic implications.
Journal ArticleDOI
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.
Morteza Naghavi,Peter Libby,Erling Falk,S. Ward Casscells,S. Ward Casscells,Silvio H. Litovsky,Silvio H. Litovsky,John A. Rumberger,Juan J. Badimon,Christodoulos Stefanadis,Pedro R. Moreno,Gerard Pasterkamp,Zahi A. Fayad,Peter Stone,Sergio Waxman,Paolo Raggi,Mohammad Madjid,Mohammad Madjid,Alireza Zarrabi,Alireza Zarrabi,Allen P. Burke,Chun Yuan,Peter J. Fitzgerald,David S. Siscovick,Chris L. de Korte,Masanori Aikawa,K.E. Juhani Airaksinen,Gerd Assmann,Christoph R. Becker,James H. Chesebro,Andrew Farb,Zorina S. Galis,Christopher L. Jackson,Ik-Kyung Jang,Wolfgang Koenig,Robert A. Lodder,Keith L. March,Jasenka Demirovic,Mohamad Navab,Silvia G. Priori,Mark D. Rekhter,Raymond D. Bahr,Scott M. Grundy,Roxana Mehran,Antonio Colombo,Eric Boerwinkle,Christie M. Ballantyne,William Insull,Robert S. Schwartz,Robert A. Vogel,Patrick W. Serruys,Göran K. Hansson,David P. Faxon,Sanjay Kaul,Helmut Drexler,Philip Greenland,James E. Muller,Renu Virmani,Renu Virmani,Paul M. Ridker,Douglas P. Zipes,Prediman K. Shah,James T. Willerson,James T. Willerson +63 more
TL;DR: The term "vulnerable patient" may be more appropriate and is proposed now for the identification of subjects with high likelihood of developing cardiac events in the near future and a quantitative method for cumulative risk assessment of vulnerable patients needs to be developed.
Journal ArticleDOI
Pathology of Drug-Eluting Stents in Humans: Delayed Healing and Late Thrombotic Risk
Michael Joner,Aloke V. Finn,Andrew Farb,Erik Mont,Frank D. Kolodgie,Elena Ladich,Robert Kutys,Kristi Skorija,Herman K. Gold,Renu Virmani +9 more
TL;DR: The Cypher and Taxus DES result in delayed arterial healing when compared with BMS of similar implant duration, and the cause of DES LST is multifactorial with delayed healing in combination with other clinical and procedural risk factors playing a role.
Journal ArticleDOI
Pathology of the Vulnerable Plaque
TL;DR: Of the three types of coronary thrombosis, a precursor lesion for acute rupture has been postulated and the non-thrombosed lesion that most resembles the acute plaque rupture is the thin cap fibroatheroma (TCFA).
Journal ArticleDOI
Coronary Risk Factors and Plaque Morphology in Men with Coronary Disease Who Died Suddenly
TL;DR: Among men with coronary disease who die suddenly, abnormal serum cholesterol concentrations - particularly elevated ratios of total cholesterol to HDL cholesterol - predispose patients to rupture of vulnerable plaques, whereas cigarette smoking predisposes patients to acute thrombosis.